A New ELISA for Use in a 3-ELISA System to Assess Concentrations of VEGF Splice Variants and VEGF₁₁₀ in Ovarian Cancer TumorsGUTIERREZ, Johnny; KONECNY, Gottfried E; HONG, Kyu et al.Clinical chemistry (Baltimore, Md.). 2008, Vol 54, Num 3, pp 597-601, issn 0009-9147, 5 p.Article

Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patientsKONECNY, Gottfried E; MENG, Y. Gloria; BERYT, Malgorzata et al.Clinical cancer research. 2004, Vol 10, Num 5, pp 1706-1716, issn 1078-0432, 11 p.Article

HER-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancerKONECNY, Gottfried E; THOMSSEN, Christoph; MÖBUS, Volker et al.Journal of the National Cancer Institute. 2004, Vol 96, Num 15, pp 1141-1151, issn 0027-8874, 11 p.Article

Tumor Hypomethylation at 6p21.3 Associates with Longer Time to Recurrence of High-Grade Serous Epithelial Ovarian CancerCHEN WANG; CICEK, Mine S; CHIEN, Jeremy et al.Cancer research (Chicago, Ill.). 2014, Vol 74, Num 11, pp 3084-3091, issn 0008-5472, 8 p.Article

Prognostic and Therapeutic Relevance of Molecular Subtypes in High-Grade Serous Ovarian CancerKONECNY, Gottfried E; CHEN WANG; GOSTOUT, Bobbie et al.Journal of the National Cancer Institute. 2014, Vol 106, Num 10, issn 0027-8874, 249.1-249.8Article

Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancerKONECNY, Gottfried E; PAULETTI, Giovanni; JÄNICKE, Fritz et al.Breast cancer research and treatment. 2010, Vol 120, Num 2, pp 481-489, issn 0167-6806, 9 p.Article

Ganitumab (AMG 479) Inhibits IGF-II-Dependent Ovarian Cancer Growth and Potentiates Platinum-Based ChemotherapyBELTRAN, Pedro J; CALZONE, Frank J; GUORONG YANG et al.Clinical cancer research (Print). 2014, Vol 20, Num 11, pp 2947-2958, issn 1078-0432, 12 p.Article

Up-regulation of LI CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomasHUSZAR, Monica; PFEIFER, Marco; ABDEL-AZIM, Samira et al.Journal of pathology (Print). 2010, Vol 220, Num 5, pp 551-561, issn 0022-3417, 11 p.Article

Intensive Dose-Dense Compared With Conventionally Scheduled Preoperative Chemotherapy for High-Risk Primary Breast CancerUNTCH, Michael; MÖBUS, Volker; KAHLERT, Stephen et al.Journal of clinical oncology. 2009, Vol 27, Num 18, pp 2938-2945, issn 0732-183X, 8 p.Article

Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancerPEGRAM, Mark D; KONECNY, Gottfried E; O'CALLAGHAN, Carminda et al.Journal of the National Cancer Institute. 2004, Vol 96, Num 10, pp 739-749, issn 0027-8874, 11 p.Article

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer SubtypesVON MINCKWITZ, Gunter; UNTCH, Michael; JACKISCH, Christian et al.Journal of clinical oncology. 2012, Vol 30, Num 15, pp 1796-1804, issn 0732-183X, 9 p.Article

Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian CarcinomaSANTISKULVONG, Chintda; KONECNY, Gottfried E; FEKETE, Mirela et al.Clinical cancer research (Print). 2011, Vol 17, Num 8, pp 2373-2384, issn 1078-0432, 12 p.Article

Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian CancerKONECNY, Gottfried E; WINTERHOFF, Boris; KALLI, Kimberly R et al.Clinical cancer research (Print). 2011, Vol 17, Num 6, pp 1591-1602, issn 1078-0432, 12 p.Article

Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2―Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study GroupsUNTCH, Michael; FASCHING, Peter A; STICKELER, Elmar et al.Journal of clinical oncology. 2011, Vol 29, Num 25, pp 3351-3357, issn 0732-183X, 7 p.Article

Intense Dose-Dense Sequential Chemotherapy With Epirubicin, Paclitaxel, and Cyclophosphamide Compared With Conventionally Scheduled Chemotherapy in High-Risk Primary Breast Cancer: Mature Results of an AGO Phase III StudyMOEBUS, Volker; JACKISCH, Christian; HARBECK, Nadia et al.Journal of clinical oncology. 2010, Vol 28, Num 17, pp 2874-2880, issn 0732-183X, 7 p.Article

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cellsKONECNY, Gottfried E; PEGRAM, Mark D; KEITH, Barry R et al.Cancer research (Baltimore). 2006, Vol 66, Num 3, pp 1630-1639, issn 0008-5472, 10 p.Article